SARC-F

There are 579 papers on SARC-F in aging research: 19 trials and 515 observational studies in people, 34 reviews.

Biomarker

579 papers study it201 more mention it223 findings

26 new papers in 30 daysSee all 780 papers on SARC-F

At a glance

Higher SARC-F scores are linked with mortality in human observational studies and with lower grip strength and poorer physical performance in older adults. Sarcopenia detection varies across populations and definitions. A human trial reports lower scores with a polyphenol-rich diet, leucine, cholecalciferol and magnesium added to rehabilitation.

223 findings in 157 papers from 2015 to 2026, 26 of them since April 2026

“men with SARC-F 2-3 (indicator of pre-sarcopenia) and SARC-F ≥ 4 had significantly increased risk of all-cause mortality [hazard ratio (HR) = 1.00, 1.77, 3.73, P < 0.001]”
Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic CohortJournal of cachexia, sarcopenia and muscle2022doi:10.1002/jcsm.12916
  • Human trial19
  • Humans515
  • In silico2

Interventions

4

Nordic walking with ankle weights

downin humans1

1 study
  1. Nordic walking with ankle weights decrease SARC-F in humans (versus Nordic walking alone) (β_adj=-1.17).

    “SARC-F score (β_adj=-1.17; p<0.001)”

    Human trialversus Nordic walking alone12 weeksn = 36

    Integrating ankle weights into Nordic walking to improve muscle strength and functional outcomes in community-dwelling older adults: A randomized controlled trial

    Rehabilitacion

More on Nordic walking with ankle weights

Polyphenol-rich diet + leucine + cholecalciferol + magnesium

downin humans1

1 study
  1. Polyphenol-rich diet + leucine + cholecalciferol + magnesium decreases SARC-F in humans (alongside rehabilitation vs rehabilitation alone) (U = 30.0, p = 0.002).

    “the study group showed significantly better subjective outcomes, including lower SARC-F scores (U = 30.0, p = 0.002)”

    Human trialalongside rehabilitation vs rehabilitation alone3 monthsn = 28

    Effect of Polyphenol-Rich Diet Combined with Leucine, Vitamin D3, and Magnesium Supplementation on Self-Reported Mobility and Health Perception in Adults at Risk of Sarcopenia: A 3-Months Quasi-Experimental Study

    Life (Basel, Switzerland)

More on Polyphenol-rich diet + leucine + cholecalciferol + magnesium

COVID-19 pandemic

upin humans1

1 study
  1. COVID-19 pandemic increases SARC-F in humans (MD = 0.67, 95%CI = [0.41, 0.93]).

    “There was a significant difference in SARC-F scores (MD = 0.67, 95%CI = [0.41, 0.93], Z = 5.00, P < .00001)”

    Review

    Impact of the COVID-19 pandemic on risk of sarcopenia: From lockdown and infection perspectives: A systematic review and meta-analysis

    Medicine

More on COVID-19 pandemic

Exercise

upin humans1

1 study
  1. Exercise improves SARC-F in humans (38.8% to 29.0%, P < 0.001).

    “At baseline, 38.8% of patients were screened as at risk for sarcopenia by SARC-F. This decreased to 29.0% after the intervention (P < 0.001).”

    Human trial12 weeksn = 31

    Prevalence of sarcopenia in patients with chronic intestinal failure-how are SARC-F and the EWGSOP algorithm associated before and after a physical exercise intervention

    JPEN. Journal of parenteral and enteral nutrition

More on Exercise

Effects

14

Mortality

no changein humans2

2 studies
  1. SARC-F was not clearly linked with mortality in humans (older adults with cardiovascular diseases admitted to the ER).

    “SARC-F was not related to mortality.”

    Humansolder adults with cardiovascular diseases admitted to the ERn = 160

    Association Between SARC-F and Clinical Outcomes in Older Adults With Cardiovascular Diseases Admitted to the Emergency Room: A Longitudinal Study

    Journal of geriatric physical therapy (2001)

  2. SARC-F was not clearly linked with mortality in humans (patients with metastatic cancer at high nutritional risk).

    “There was no association between the risk of sarcopenia and one-year mortality in patients with metastatic cancer.”

    Humanspatients with metastatic cancer at high nutritional risk

    The Significance of SARC-F Scores in One-Year Mortality of Adults with High Nutritional Risk with Cancer

    Nutrition and cancer

Appendicular lean soft tissue

no changein humans1

1 study
  1. SARC-F was not clearly linked with appendicular lean soft tissue in humans (Kawakami-defined low muscle mass) (AUC 0.563 (95% CI 0.480-0.646)).

    “SARC-F did not discriminate Kawakami-defined low muscle mass: AUC 0.563 (95% CI 0.480-0.646) in women”

    HumansKawakami-defined low muscle massfemales

    Equation-dependent anthropometric muscle-mass estimates and functional screening limitations in home-bound older adults

    Clinical nutrition ESPEN

More on Appendicular lean soft tissue

Body composition parameters

no changein humans1

1 study
  1. SARC-F was not clearly linked with body composition parameters in Hindi-speaking cancer patients (P > 0.05).

    “No statistically significant correlations were observed between SARC-F scores and age, performance status, or body composition parameters (all P > 0.05).”

    Humansin Hindi-speaking cancer patientsHindi translated questionnairen = 100

    Translation of the strength, assistance in walking, rising from a chair, climbing stairs, and falls questionnaire into Hindi

    World journal of methodology

Functional independence

downin humans1

1 study
  1. SARC-F is linked with lower functional independence in humans (hospitalized for hip fracture) (-2.85 points (95% CI, -3.45 to -2.24)).

    “each 1-point increase in SARC-F was associated with a 2.85-point reduction in the Barthel Index (95% CI, −3.45 to −2.24; p < 0.001)”

    Humanshospitalized for hip fracturen = 330

    Association Between the Sarc-f Score and Functional Independence in Older Adults Hospitalized for Hip Fracture

    Journal of Health Sciences

Rectus femoris muscle elasticity

no changein humans1

1 study
  1. SARC-F was not clearly linked with rectus femoris muscle elasticity in humans (age- and sex-adjusted) (p = 0.116).

    “In the age- and sex-adjusted model, this association was no longer significant (p = 0.116).”

    Humansage- and sex-adjustedn = 140

    Assessing the ability of SARC-F to reflect elastography-based muscle quality in older adults

    Acta clinica Belgica

Pneumonia

no changein humans1

1 study
  1. SARC-F was not clearly linked with pneumonia in humans (stable schizophrenia patients aged ≥50 years).

    “However, in stable schizophrenia patients with SARC-F scores ≥4 and < 4, this study has not yet observed a similar pattern for pneumonia risk.”

    Humansstable schizophrenia patients aged ≥50 yearsn = 335

    SARC-F, SARC-CalF, and SARC-F+EBM as practical predictive tools for the risk of pneumonia in patients with stable schizophrenia-a prospective study

    Heliyon

More on Pneumonia

Walking time

downin humans1

1 study
  1. SARC-F is linked with lower walking time in humans (older hospitalised patients) (-0.07 h).

    “For every unit increase in SARC-F, there was a 0.07 h shorter walking time upon discharge.”

    Humansolder hospitalised patientsn = 31

    Diminished Physical Activity in Older Hospitalised Patients with and without COVID-19

    Journal of clinical medicine

Overall survival

downin humans1

1 study
  1. SARC-F is linked with lower overall survival in humans (liver disease) (78.3% vs 90.1% (p = 0.0181)).

    “The 1-year cumulative overall survival ratio in patients with SARC-F ≥ 1 (n = 159) and SARC-F 0 (n = 110) was 78.3% and 90.1% (p = 0.0181).”

    Humansliver disease1-yearn = 269

    Accurate SARC-F Score in Patients with Liver Disease

    Diagnostics (Basel, Switzerland)

SF-36 physical functioning

downin humans1

1 study
  1. SARC-F is linked with lower SF-36 physical functioning in humans (cardiovascular disease and cognitive impairment) (all P < 0.001).

    “Sarcopenia (SARC-F score ≥ 4 points) was associated with poorer motor function test outcomes and SF-36PF scores (all P < 0.001).”

    Humanscardiovascular disease and cognitive impairmentn = 408

    SARC-F predicts poor motor function, quality of life, and prognosis in older patients with cardiovascular disease and cognitive impairment

    Experimental gerontology

More on SF-36 physical functioning

T-score

no changein humans1

1 study
  1. SARC-F was not clearly linked with T-score in patients assessed after COVID-19 vs non-COVID-19.

    “No correlation of the SARC F and SPPB scores with the T score values obtained by osteo-densitometry was found.”

    Humansin patients assessed after COVID-19 vs non-COVID-19n = 157

    The Effects of the 'Catabolic Crisis' on Patients' Prolonged Immobility after COVID-19 Infection

    Medicina (Kaunas, Lithuania)

More on T-score

All 14

Upstream

4

Age

no changein humans1upin humans1OR 1.081

2 studies
  1. Age was not clearly linked with SARC-F in humans (r = 0.1, p = 0.3).

    “not with age (r = 0.1, p = 0.3) or BMI (r = 0.1, p = 0.4)”

    Humansn = 100

    Evaluation of Prevalence and Risk Factors of Possible Sarcopenia Based on SARC-F in Adults Over 60 in Tegucigalpa, Honduras: A Cross-Sectional Study

    Health science reports

  2. Age is linked with higher SARC-F in humans (systemic sclerosis) (OR 1.081 (95% CI 1.012-1.154, p = 0.020)).

    “A multivariate logistic regression analysis identified age as the only factor significantly influencing the SARC-F score, with an odds ratio of 1.081 (95% CI 1.012-1.154, p = 0.020).”

    Humanssystemic sclerosisn = 80

    Assessment of Factors Related to Sarcopenia in Patients with Systemic Sclerosis

    Journal of clinical medicine

Body composition disorders

no changein humans1

1 study
  1. Body composition disorders were not clearly linked with SARC-F in patients with coronary artery disease.

    “The average score on the SARC-F questionnaire did not differ significantly in the groups of patients with various BCD.”

    Humansin patients with coronary artery diseasen = 720

    VARIOUS BODY COMPOSITION DISORDERS IN ELDERLY PATIENTS WITH ATHEROSCLEROSIS OF VASCULAR BEDS

    Complex Issues of Cardiovascular Diseases

Atrial fibrillation

upin humans1

1 study
  1. Atrial fibrillation is linked with higher SARC-F in humans.

    “Participants with AF exhibited significantly higher SARC-F and SarQol scores.”

    Humans

    Sarcopenia in atrial fibrillation: a prospective study

    Turkish journal of medical sciences

More on Atrial fibrillation

Gastrointestinal disease type

no changein humans1

1 study
  1. Gastrointestinal disease type was not clearly linked with SARC-F in humans (gastrointestinal diseases) (17.5% in UGD, 12.0% in LGD, 17.3% in BPD, and 13.7% in LD (overall p = 0.1235)).

    “The proportion of SARC-F ≥4 points in groups of UGD, LGD, BPD, and LD were 17.5% (57/326) in UGD, 12.0% (43/357) in LGD, 17.3% (72/416) in BPD, and 13.7% (25/183) in LD, respectively (overall p = 0.1235).”

    Humansgastrointestinal diseasesn = 1,282

    Comparison of SARC-F Score among Gastrointestinal Diseases

    Journal of clinical medicine

Associations

114

Sarcopenia

upin humans29downin humans3no changein humans2OR 1.447–4.788

34 studies
  1. SARC-F predicts sarcopenia in humans (AUC 0.654).

    “both showed higher AUCs than SARC-F (AUC: SARC-F 0.654, SARC-CalF 0.808, CC 0.822; Figure 1).”

    HumansPatients admitted for acute cardiovascular disease treatment; sarcopenia defined by AWGS 2025n = 398

    Diagnostic performance of SARC-F, SARC-CalF, and calf circumference for sarcopenia in middle-aged patients with cardiovascular disease

    ESC Congress 2026 abstract

  2. SARC-F is linked with a higher risk of sarcopenia in humans (adjusted OR 3.34, p<0.001).

    “SARC-F score ≥4 (adjusted OR 3.34)”

    Humansn = 1,474

    Development of a Sarcopenia Score for Sarcopenia Screening in Community-Dwelling Older Adults

    Journal of the Medical Association of Thailand

  3. SARC-F predicts sarcopenia in humans (screening possible sarcopenia) (AUC 0.67, 95% CI 0.622-0.710).

    “it showed poor discriminative ability in detecting possible sarcopaenia (area under the ROC curve=0.67; 95% confidence interval=0.622-0.710; P<0.001).”

    Humansscreening possible sarcopenian = 578

    SARC-F score compared with hand grip strength for screening possible sarcopaenia among community-dwelling older adults: A multi-centre cross-sectional study in Malaysia

    Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

  4. SARC-F predicts sarcopenia in humans (overall population) (AUC = 0.693).

    “ROC analysis revealed that SARC-F had the highest diagnostic accuracy in the overall population (AUC = 0.693)”

    Humansoverall populationn = 347

    Sex-specific predictive ability of SARC-F and SARC-CalF for ultrasound-based sarcopenia in older adults

    BMC geriatrics

  5. SARC-F predicts sarcopenia in humans (for probable sarcopenia in patients with rheumatoid arthritis) (sensitivity 86.2%, NPV 91.3%, specificity 54.5%).

    “SARC-F showed high sensitivity (86.2%) and NPV (91.3%) for probable sarcopenia but had low specificity (54.5%) and poor discrimination for confirmed (AUC: 0.43) and severe (AUC: 0.44) cases.”

    Humansfor probable sarcopenia in patients with rheumatoid arthritisn = 106

    Diagnostic accuracy of SARC-F and SARC-CalF as sarcopenia screening instruments in rheumatoid arthritis according to European Working Group on Sarcopenia in Older People

    Physiotherapy theory and practice

  6. SARC-F predicts sarcopenia in humans (chronic hemodialysis) (OR 2.422, 95 % CI 1.676-3.501).

    “higher baseline SARC-F scores (OR 2.422, 95 % CI 1.676-3.501) were associated with increased risk”

    Humanschronic hemodialysisone yearn = 146

    Risk factors for incident or persistent SARC-F-defined sarcopenia in patients with end-stage kidney disease: a cohort study

    Journal of the Formosan Medical Association = Taiwan yi zhi

  7. SARC-F predicts sarcopenia in humans (rheumatoid arthritis) (AUC 0.60, sensitivity 34.8%, specificity 84.5%).

    “The areas under the receiver operating characteristic (ROC) curve for the SARC-F, SARC-CalF, MSRA-7, MSRA-5, and modified MSRA-5 questionnaires were 0.60, 0.74, 0.65, 0.62, and 0.65, respectively”

    Humansrheumatoid arthritisn = 299

    Performance of Five Thai Versions of Sarcopenia Screening Questionnaires (SARC-F, SARC-CalF, MSRA-7, MSRA-5, and Modified MSRA-5) in Thai Rheumatoid Arthritis Patients: A Cross-Sectional Study

    Journal of clinical medicine

  8. SARC-F predicts sarcopenia in humans (outpatient geriatric clinics) (AUC 0.91 (95%CI: 0.86-0.95)).

    “The area under the curve (AUC) was 0.91 (95%CI: 0.86-0.95).”

    Humansoutpatient geriatric clinicsn = 200

    Validity and reliability of the Persian version of the SARC-F questionnaire among Iranian older adults

    BMC geriatrics

  9. SARC-F predicts sarcopenia in humans (screening threshold ≥2) (AUC 0.77 (95% CI 0.67-0.88), sensitivity 0.78, specificity 0.75).

    “A SARC-F cut point of ≥2 yielded an area under the curve of 0.77 (95% CI 0.67-0.88), with sensitivity of 0.78, specificity of 0.75”

    Humansscreening threshold ≥2n = 204

    Assessment of SARC-F Sensitivity for Probable Sarcopenia Among Community-Dwelling Older Adults: Cross-Sectional Questionnaire Study

    JMIRx med

  10. SARC-F predicts sarcopenia in community-dwelling older adults (AUC 0.530, sensitivity 0.07, specificity 0.99).

    “In the case-finding step, the sensitivity for Scenarios1 to 4 was 0.86,0.84,0.23 and 0.07, respectively; specificity was 0.57,0.58,0.93 and 0.99, respectively; and the AUCs were 0.717,0.710,0.581 and 0.530, respectively.”

    Humansin community-dwelling older adultsn = 2,453

    Evaluation of sarcopenia diagnosis strategies in Chinese community-dwelling older adults based on the 2019 Asian Working Group guidelines: a cross-sectional study

    BMC geriatrics

All 34

More on Sarcopenia

Mortality

upin humans15OR 1.18–8.34

15 studies
  1. SARC-F is associated with mortality in humans (hospitalized) (HR ranging from 3.77 to 9.47).

    “Cox proportional hazards analysis revealed that a SARC-F score ≥1 was associated with significantly higher hazard ratios across all age groups (ranging from 3.77 to 9.47; all P < 0.01).”

    Humanshospitalizedn = 12,743

    SARC-F questionnaire and its predictive value for mortality risk in hospitalized younger adults: A retrospective study

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  2. SARC-F predicts mortality in humans (hospitalized) (AUC 0.721 (IQR 0.678-0.764)).

    “SARC-F scores at admission had a significant area under the ROC curve (0.721, IQR 0.678-0.764; P < 0.001) for predicting mortality.”

    Humanshospitalizedn = 12,743

    SARC-F questionnaire and its predictive value for mortality risk in hospitalized younger adults: A retrospective study

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  3. SARC-F predicts mortality in humans (cancer patients at high nutritional risk) (p = 0.002).

    “There was an association between sarcopenia risk and one-year mortality in all cancer patients (p = 0.002)”

    Humanscancer patients at high nutritional riskn = 185

    The Significance of SARC-F Scores in One-Year Mortality of Adults with High Nutritional Risk with Cancer

    Nutrition and cancer

  4. SARC-F predicts mortality in humans (acutely decompensated heart failure) (adjusted OR = 1.18 (CI95% 1.03–1.33), p = 0.003).

    “HGS (β = -0.73 ± 0.03, p = 0.008) and SARC-F [adjusted OR = 1.18 (CI95% 1.03–1.33), p = 0.003] resulted independently associated with mortality.”

    Humansacutely decompensated heart failure30 daysn = 184

    Usefulness of an early sarcopenia screening in predicting short-term mortality in older patients discharged for acute heart failure

    Research SquarePreprint

  5. SARC-F is linked with a higher risk of mortality in humans (older patients with cardiovascular disease) (HR 2.02 (95% CI: 1.39 – 2.92, p < 0.001)).

    “A SARC-F score of 4 or higher was significantly associated with an increased risk of all-cause mortality, with HR of 2.02 (95% CI: 1.39 – 2.92, p < 0.001)”

    Humansolder patients with cardiovascular disease6 monthsn = 285

    Association between SARC-F scores and risk of adverse outcomes in older patients with cardiovascular disease: a prospective study at a tertiary hospital in Ho Chi Minh City

    Research SquarePreprint

  6. SARC-F predicts mortality in humans (cancer) (HR = 3.1, p < 0.001).

    “Incorporating SARC-F improved survival prognostication beyond SMI and SMD (HR = 3.1; p < 0.001; Harrel's C from 0.73 to 0.76).”

    Humanscancern = 212

    SARC-F as a screening tool to detect computed tomography-based sarcopenia and myosteatosis among older adults with cancer

    Cancer medicine

  7. SARC-F is linked with a higher risk of mortality in humans (HR 1.6, 95% CI 1.1-2.3).

    “Abnormal grip, SARC-F, and FRAIL scale assessments were associated with higher mortality risk (HR [95%CI] = 2.0 [1.4-2.9], 1.6 [1.1-2.3], 2.0 [1.4-2.8]).”

    Humans

    Clinical, functional, and opportunistic CT metrics of sarcopenia at the point of imaging care: analysis of all-cause mortality

    Skeletal radiology

  8. SARC-F predicts mortality in humans (liver disease) (AUC 0.60, sensitivity 0.57, specificity 0.62).

    “In the receiver operating curve (ROC) analysis based on the prognosis for the SARC-F score, the area under the ROC was 0.60.”

    Humansliver diseasen = 269

    Accurate SARC-F Score in Patients with Liver Disease

    Diagnostics (Basel, Switzerland)

  9. SARC-F is associated with mortality in humans (COVID-19) (34% greater risk of death, p = 0.003).

    “One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death”

    HumansCOVID-19n = 163

    Factors associated with mortality in hospitalised, non-severe, older COVID-19 patients - the role of sarcopenia and frailty assessment

    BMC geriatrics

  10. SARC-F is linked with a higher risk of mortality in humans (SARC-F score ≥ 4 vs 0-1, adjusted) (HR = 3.73, P < 0.001).

    “men with SARC-F 2-3 (indicator of pre-sarcopenia) and SARC-F ≥ 4 had significantly increased risk of all-cause mortality [hazard ratio (HR) = 1.00, 1.77, 3.73, P < 0.001]”

    HumansSARC-F score ≥ 4 vs 0-1, adjusted6.8 yearsmales

    Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort

    Journal of cachexia, sarcopenia and muscle

All 17

Handgrip strength

downin humans7upin humans1

8 studies
  1. SARC-F is associated with handgrip strength in humans (Subacute stroke survivors; non-affected side; adjusted for age, sex, and time since stroke) (Adjusted coefficient −5.90 kg (95% CI −11.22 to −0.59)).

    “Adjusted HGS coefficients were −5.90 kg (95% CI −11.22 to −0.59; p = 0.030) for SARC-F”

    HumansSubacute stroke survivors; non-affected side; adjusted for age, sex, and time since stroken = 86

    Malnutrition, Sarcopenia Risk Screening, and Muscle Function in Subacute Stroke Survivors Admitted to Long-Term Care Rehabilitation Units

    Medical sciences (Basel, Switzerland)

  2. SARC-F is associated with handgrip strength in humans (evaluated for osteoporosis) (r = -0.264, p = 0.013).

    “SARC-F scores were inversely correlated with handgrip strength (r = -0.264; p = 0.013)”

    Humansevaluated for osteoporosisfemalesn = 96

    Association of Mediterranean Diet Adherence with Self-Reported Muscle-Related Functional Status and Fracture Probability in Postmenopausal Women Evaluated for Osteoporosis: A Cross-Sectional Study

    Nutrients

  3. SARC-F is associated with handgrip strength in humans (hospitalized for hip fracture) (r = -0.40).

    “The SARC-F score showed a strong negative correlation with the Barthel Index (r = −0.72; p < 0.001) and a moderate correlation with handgrip strength (r = −0.40; p < 0.001).”

    Humanshospitalized for hip fracturen = 330

    Association Between the Sarc-f Score and Functional Independence in Older Adults Hospitalized for Hip Fracture

    Journal of Health Sciences

  4. SARC-F predicts handgrip strength in humans (older Indian patients with solid tumor) (sensitivity 29.6%, specificity 83.6%).

    “SARC-F has a low sensitivity in identifying patients with low handgrip (sensitivity 29.6%, specificity 83.6%, negative predictive value [NPV] 45.4%, positive predictive value [PPV] 72.1%).”

    Humansolder Indian patients with solid tumorn = 1,025

    Screening for poor muscle strength in older Indian patients with solid tumor using SARC-F questionnaire and handgrip

    Journal of geriatric oncology

  5. SARC-F predicts handgrip strength in humans (outpatient clinic attendees) (AUC = 0.705).

    “For HGS and STST, a cut-off of ≥2 yielded the most favorable discrimination (AUC = 0.705 and 0.735, respectively).”

    Humansoutpatient clinic attendeesn = 1,355

    Optimising SARC-F cut-off for sarcopenia screening: A comparative analysis with muscle strength and physical performance tests

    Nutrition (Burbank, Los Angeles County, Calif.)

  6. SARC-F is associated with handgrip strength in humans (older adults) (ρ = -0.42, p < 0.001).

    “and handgrip strength (ρ = -0.42; p < 0.001), supporting convergent validity.”

    Humansolder adultsn = 153

    Translation, Cross-Cultural Adaptation, and Validation of the Croatian Version of the SARC-F Questionnaire for Assessing Sarcopenia in Older Adults

    Healthcare (Basel, Switzerland)

  7. SARC-F is associated with handgrip strength in humans (p < 0.05).

    “SARC-F was significantly correlated with SMM, SMI, HGS, and HGS/SMM in both men and women (p < 0.05).”

    Humansn = 205

    Association of SARC-F with muscle mass, strength, and quality derived from bioelectrical impedance spectroscopy for sarcopenia assessment

    Scientific reports

  8. SARC-F is associated with handgrip strength in humans.

    “In contrast, right-hand grip strength was negatively correlated with SARC-F.”

    Humansfemalesn = 19

    Relationship between plantar pressure distribution during the stance phase of gait and suspicion of sarcopenia in elderly Women: A cross-sectional pilot study

    Journal of bodywork and movement therapies

Physical function

downin humans5upin humans3

8 studies
  1. SARC-F predicts physical function in humans (community-dwelling older adults) (AUC 0.60 to 0.80).

    “Both the SARC-F and SARC-CalF demonstrated acceptable discriminative ability for identifying functional impairment, with area under the curve (AUC) values ranging from 0.60 to 0.80”

    Humanscommunity-dwelling older adultsn = 253

    Evaluating the Discriminative Performance of SARC-F and SARC-CalF in Identifying Functional Impairment in Community-Dwelling Older Adults

    Physiotherapy research international : the journal for researchers and clinicians in physical therapy

  2. SARC-F is associated with physical function in humans (adjusted for age and sex).

    “Total SARC-F score was consistently associated with muscle strength, physical performance, PROs and DXA components.”

    Humansadjusted for age and sex

    Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spondyloarthritis

    RMD open

  3. SARC-F is associated with physical function in humans (systemic lupus erythematosus) (p < 0.01).

    “Participants with SARC-F ≥4 had worse organ damage and functional measures than those with SARC-F <4 (all p < 0.01).”

    Humanssystemic lupus erythematosusfemalesn = 47

    Association of a self-report screening tool for sarcopenia (SARC-F) with functional status outcomes in systemic lupus erythematosus

    Lupus

  4. SARC-F is associated with physical function in humans (cardiovascular disease, SARC-F scores 1-3) (all P < 0.001).

    “every 1 point increase in the SARC-F score was associated with lower physical functions such as lower muscle strength and shorter walking distance (all P < 0.001).”

    Humanscardiovascular disease, SARC-F scores 1-3n = 1,066

    Screening for sarcopenia with SARC-F in older patients hospitalized with cardiovascular disease

    European journal of cardiovascular nursing

  5. SARC-F predicts physical function in humans (cancer) (sensitivity: 80%, specificity: 75.7%).

    “When low grip strength per FNIH was combined with low SPPB, SARC-F demonstrated high sensitivity (80%) and specificity (75.7%).”

    Humanscancern = 80

    Performance of the SARC-F in identifying low grip strength and physical performance in older adults with cancer

    Journal of geriatric oncology

  6. SARC-F is associated with physical function in humans (patients undergoing hemodialysis).

    “The SARC-F and SARC-CalF were both associated with physical function, but not with SMM.”

    Humanspatients undergoing hemodialysisn = 30

    SARC-F and SARC-CalF are associated with sarcopenia traits in hemodialysis patients

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

  7. SARC-F is associated with physical function in humans.

    “Patients in the sarcopenia group had consistently poorer physical function even after adjusting for covariates.”

    HumansJapanese hospitalized patients with cardiovascular disease; SARC-F ≥4 versus SARC-F <4, adjusted for covariatesn = 235

    Utility of SARC-F for Assessing Physical Function in Elderly Patients With Cardiovascular Disease

    Journal of the American Medical Directors Association

  8. SARC-F predicts physical function in humans (score ≥ 4).

    “AAH participants with SARC-F scores ≥ 4 had more Instrumental Activity of Daily Living (IADL) deficits, slower chair stand times, lower grip strength, lower short physical performance battery scores”

    Humansscore ≥ 4

    SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes

    Journal of cachexia, sarcopenia and muscle

Frailty

upin humans5OR 12.52

5 studies
  1. SARC-F is associated with frailty in humans (standardized OR 12.52, 95% CI: 8.90-23.91, p < 0.001).

    “SARC-F was the only variable significantly associated with frailty category (p < 0.001).”

    Humansn = 100

    Benchmarking Interpretable Machine Learning for Frailty Screening in Older Adults Using Routine Clinical Variables with and Without SARC-F: A Pilot Diagnostic Study

    Diagnostics (Basel, Switzerland)

  2. SARC-F is associated with frailty in humans (type two intestinal failure) (rs 0.43, p < 0.001).

    “SARC-F was correlated with RCFS (rs 0.43, p < 0.001)”

    Humanstype two intestinal failuren = 76

    The relationships between sarcopenia, frailty, bioelectrical impedance analysis, and anthropometry in patients with type two intestinal failure

    Clinical nutrition ESPEN

  3. SARC-F predicts frailty in humans (Emergency Department patients) (AUC 0.92, 95% CI 0.86-0.98, P<0.001).

    “SARC-F (AUC 0.92, 95% Confidence Interval (CI) 0.86-0.98, P<0.001; Sensitivity 79.0%, and Specificity 88.9%) performed best for frailty detection as defined by FI”

    HumansEmergency Department patients

    SARC-F at the Emergency Department: Diagnostic Performance for Frailty and Predictive Performance for Reattendances and Acute Hospitalizations

    The journal of nutrition, health & aging

  4. SARC-F predicts frailty in humans (Frailty assessed by the modified Fried scale) (AUC 0.807 (95% CI 0.76–0.84); cutoff ≥2: sensitivity 74.1%, specificity 73.7%).

    “SARC-F cut-off ≥2 presented the best balance between sensitivity and specificity (sensitivity: 74.1% vs. specificity: 73.7%) to identify frailty”

    HumansFrailty assessed by the modified Fried scale70.7% femalesn = 447

    SARC-F Questionnaire Detects Frailty in Older Adults

    The journal of nutrition, health & aging

  5. SARC-F predicts frailty in humans (screening).

    “Recently, it has also been suggested as a reasonable screening test for frailty.”

    Reviewscreening

    SARC-F and other screening tests for sarcopenia

    Current opinion in clinical nutrition and metabolic care

Grip strength

downin humans3

3 studies
  1. SARC-F is associated with grip strength in kidney transplant patients.

    “revealed a negative correlation between SARC-F and total muscle mass, muscle percentage, skeletal muscle mass, skeletal muscle index, grip strength, and walking speed parameters”

    Humansin kidney transplant patients

    Should we use the SARC-F score in sarcopenia screening in kidney transplant patients?

    Irish journal of medical science

  2. SARC-F is associated with grip strength in humans (men 19.0 kg vs 28.0 kg, P<0.001; women 14.0 kg vs 18.0 kg, P<0.001).

    “the median HGS was significantly lower in the high-risk SARC-F group for both men (19.0 kg vs 28.0 kg, P<0.001) and women (14.0 kg vs 18.0 kg, P<0.001).”

    Humansn = 578

    SARC-F score compared with hand grip strength for screening possible sarcopaenia among community-dwelling older adults: A multi-centre cross-sectional study in Malaysia

    Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

  3. SARC-F is associated with grip strength in humans (p = 0.013).

    “SARC-F with Handgrip strength (p = 0.013)”

    Humansn = 100

    Validation of the Italian Version of the Rapid Geriatric Assessment in Community-Dwelling Older Adults

    Geriatrics (Basel, Switzerland)

Length of hospital stay

upin humans3OR 2.34

3 studies
  1. SARC-F predicts length of hospital stay in humans (postoperative lumbar disc herniation surgery; prolonged LOS > 5 days) (aOR 2.79, 95% CI 1.03–7.57).

    “and SARC-F (aOR 2.79, 95% CI 1.03–7.57)”

    Humanspostoperative lumbar disc herniation surgery; prolonged LOS > 5 daysn = 111

    Comparison of simple bedside tests for probable sarcopenia and their association with postoperative recovery after lumbar disc herniation surgery: a pilot study

    Research SquarePreprint

  2. SARC-F is associated with length of hospital stay in humans (COVID-19) (16.8 h longer hospital stay, p = 0.01).

    “One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death, and 16.8 h longer hospital stay (p = 0.01).”

    HumansCOVID-19n = 163

    Factors associated with mortality in hospitalised, non-severe, older COVID-19 patients - the role of sarcopenia and frailty assessment

    BMC geriatrics

  3. SARC-F is associated with length of hospital stay in patients admitted to a hospital with a suspected infarction (OR 2.34, 95% CI 1.09-5.04, p = 0.030).

    “Risk of sarcopenia was independently associated with longer LOS (odds ratio, 2.34; 95% CI, 1.09-5.04; p = 0.030)”

    Humansin patients admitted to a hospital with a suspected infarction

    SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event

    Nutrients

Depressive symptoms

upin humans2

2 studies
  1. SARC-F is associated with depressive symptoms in humans (Patients on maintenance hemodialysis; multivariable analysis) (B = 0.39 per point, p = 0.009).

    “In multivariable analysis, age and SARC-F were independently associated with depressive symptoms (SARC-F: B = 0.39 per point, p = 0.009).”

    HumansPatients on maintenance hemodialysis; multivariable analysisn = 95

    Association of Sarcopenia Risk with Depressive and Anxiety Symptoms in Patients on Maintenance Hemodialysis: A Cross-Sectional Study

    Medicina (Kaunas, Lithuania)

  2. SARC-F is associated with depressive symptoms in sarcopenic individuals (adjusted P for trend = 0.0028).

    “There was a significant dose-dependent association between SARC-F scores and depressive symptoms in sarcopenic individuals (adjusted P for trend = 0.0028).”

    Humansin sarcopenic individuals

    Association between Sarcopenia and Depressive Symptoms in Community-Dwelling People Aged 40 Years and Older

    The Tohoku journal of experimental medicine

More on Depressive symptoms

SarQoL

downin humans2

2 studies
  1. SARC-F is associated with SarQoL in peritoneal dialysis patients (r=-0.77, p<0.0001).

    “Strong inverse relationships were observed between SarQoL and SARC-F scores (r=-0.77, p<0.0001) and age (r=-0.50, p=0.003).”

    Humansin peritoneal dialysis patientsn = 32

    Applicability and clinical significance of the SarQoL (Sarcopenia Quality of Life) tool in peritoneal dialysis patients: A preliminary report

    Nefrologia

  2. SarQoL is associated with SARC-F in humans (probable sarcopenia) (r = - 0.45; p < 0.001).

    “SARC-F (r = - 0.45; p < 0.001)”

    Humansprobable sarcopenian = 125

    Performance of the SarQoL quality of life tool in a UK population of older people with probable sarcopenia and implications for use in clinical trials: findings from the SarcNet registry

    BMC geriatrics

More on SarQoL

Sarcopenic obesity

upin humans2

2 studies
  1. SARC-F predicts sarcopenic obesity in humans (hospitalised older adults) (AUC 0.56, 95% CI 0.53–0.60).

    “SARC-F showed the highest overall discriminatory ability (AUC 0.56, 95% CI 0.53–0.60), with a cut-off score of 2 providing a reasonable balance between sensitivity and specificity.”

    Humanshospitalised older adultsn = 1,233

    Performance of Four Sarcopenia Screening Tools for Possible Sarcopenic Obesity in Hospitalised Patients

    Research SquarePreprint

  2. SARC-F predicts sarcopenic obesity in humans with high BMI or WC (sensitivity men 5.68%, women 17.82%; specificity men 99.03%, women 94.35%).

    “SARC-F (≥4) with high BMI or WC demonstrated low sensitivity (men, 5.68%; women, 17.82%) but high specificity (men, 99.03%; women, 94.35%)”

    Humanswith high BMI or WCn = 2,020

    Validation of Sarcopenic Obesity Screening Tools: A Cross-Sectional Analysis Based on ESPEN and EASO Criteria

    Medicina (Kaunas, Lithuania)

More on Sarcopenic obesity

All 114

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    SARC-F predicts mortality in hospitalized adults and cancer cohorts and is associated with muscle strength and physical function in human studies. Sarcopenia detection varies by population and definition. A study of older emergency-department patients with cardiovascular disease finds no mortality association, despite associations with mechanical ventilation and length of stay.

  2. Summary rewritten as its findings changed.

    As it read before

    In human cohorts, SARC-F associates with walking speed, grip strength, and total muscle mass in kidney transplant recipients, and predicts urinary incontinence in females.

  3. Summary written from the findings.

Latest

Dec 2025: 15Jan 2026: 31Feb 2026: 24Mar 2026: 17Apr 2026: 21May 2026: 17Jun 2026: 27Jul 2026: 20Aug 2026: 17Sep 2026: 22Oct 2026: 15Nov 2026: 14240 papers in 12 months

See all 780 papers on SARC-F